To view this email as a web page, click here.
October 2, 2019
 
linagliptin Safe for Diabetes Patients with Elevated Cardiovascular Risk
Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.
Read more
 
ADVERTISEMENT
Diabetes Drug Dapagliflozin Prevents Worsening Heart Failure, Study Shows
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes.
Read more
 
Image IQ: Hemodialysis and a plaque on the leg
Image IQ: A 60-year-old woman undergoing hemodialysis for chronic kidney disease developes a smooth plaque on her leg. What's your diagnosis?
Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.